

Trevor F Cox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8638955/publications.pdf>

Version: 2024-02-01

60
papers

3,850
citations

257450

24
h-index

155660

55
g-index

63
all docs

63
docs citations

63
times ranked

5652
citing authors

#	ARTICLE	IF	CITATIONS
1	Kernel hazard estimation for visualisation of the effect of a continuous covariate on <sc>timeâ€toâ€event</sc> endpoints. Pharmaceutical Statistics, 2022, 21, 514-524.	1.3	2
2	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, 2020, 8, 762-772.	11.4	78
3	Dual-focus magnification, high-definition endoscopy improves pathology detection in direct-to-test diagnostic upper gastrointestinal endoscopy. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 19-24.	0.9	5
4	Subclinical ochronosis features in alkaptonuria: a cross-sectional study. BMJ Innovations, 2019, 5, 82-91.	1.7	15
5	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, 2017, 18, 486-499.	10.7	60
6	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 2017, 66, 1665-1676.	12.1	212
7	The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial. Trials, 2016, 17, 24.	1.6	17
8	A practical divergence measure for survival distributions that can be estimated from Kaplan-Meier curves. Statistics in Medicine, 2016, 35, 2406-2421.	1.6	8
9	Correlated components. Stat, 2016, 5, 45-56.	0.4	2
10	Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4â€weeks of treatment. Annals of the Rheumatic Diseases, 2016, 75, 362-367.	0.9	123
11	Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 2016, 114, 510-518.	6.4	17
12	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	7.0	69
13	Assessing the Quality of Care for Dying Patients From the Bereaved Relatives' Perspective: Further Validation of â€Evaluating Care and Health Outcomesâ€for the Dyingâ€. Journal of Pain and Symptom Management, 2014, 47, 687-696.	1.2	20
14	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. Journal of the National Cancer Institute, 2014, 106, djt347.	6.3	231
15	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. Journal of Clinical Oncology, 2014, 32, 504-512.	1.6	351
16	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, 2014, 15, 829-840.	10.7	296
17	Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Molecular Cancer, 2014, 13, 114.	19.2	54
18	Testing the Equivalence of Survival Distributions using PP- and PPP-Plots. International Journal of Statistics in Medical Research, 2014, 3, 161-173.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Bayesian analysis unravels pancreas-cancer adjuvant therapy. Lancet Oncology, The, 2013, 14, 1034-1035.	10.7	6
20	Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis. Critical Care, 2013, 17, R49.	5.8	32
21	Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design. Trials, 2013, 14, .	1.6	2
22	The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints. Trials, 2013, 14, .	1.6	0
23	Testing the equivalence of survival distributions using PP- and PPP-plots. Trials, 2013, 14, .	1.6	0
24	Adjuvant Chemotherapy for Resected Periapillary Adenocarcinoma—Reply. JAMA - Journal of the American Medical Association, 2012, 308, 1855.	7.4	3
25	Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periapillary Adenocarcinoma. JAMA - Journal of the American Medical Association, 2012, 308, 147.	7.4	499
26	Adjuvant Therapy for Pancreatic Cancer. Recent Results in Cancer Research, 2012, 196, 65-88.	1.8	22
27	The Value of Source Data Verification in a Cancer Clinical Trial. PLoS ONE, 2012, 7, e51623.	2.5	58
28	Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study. Pancreatology, 2011, 11, 535-545.	1.1	93
29	A quantitative assessment of alkaptonuria. Journal of Inherited Metabolic Disease, 2011, 34, 1153-1162.	3.6	48
30	Natural history of alkaptonuria revisited: analyses based on scoring systems. Journal of Inherited Metabolic Disease, 2011, 34, 1141-1151.	3.6	69
31	A robust parameterisation for the analysis of survival data in the presence of covariates with extreme value observations. Trials, 2011, 12, .	1.6	0
32	The effect of toothpaste concentration on enamel and dentine wear in vitro. Journal of Dentistry, 2010, 38, 974-979.	4.1	42
33	The protective nature of pellicle towards toothpaste abrasion on enamel and dentine. Journal of Dentistry, 2008, 36, 360-368.	4.1	59
34	Evaluation of a new silica whitening toothpaste containing blue covarine on the colour of anterior restoration materials in vitro. Journal of Dentistry, 2008, 36, 26-31.	4.1	17
35	Nonparametric discrimination of time series data. Metrika, 2004, 59, 13-20.	0.8	3
36	Ch. 16. Multidimensional scaling in process control. Handbook of Statistics, 2003, , 609-623.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Multidimensional scaling used in multivariate statistical process control. Journal of Applied Statistics, 2001, 28, 365-378.	1.3	27
38	A General Weighted Two-Way Dissimilarity Coefficient. Journal of Classification, 2000, 17, 101-121.	2.2	16
39	Multidimensional Scaling, Second Edition. Monographs on Statistics and Applied Probability, 2000, , .	0.3	575
40	A robust logistic discrimination model. Statistics and Computing, 1997, 7, 155-161.	1.5	4
41	Time-series analysis of urethral electrical conductance measurements in the assessment of unstable urethral pressure: Results in normal patients and in those with genuine stress incontinence. Neurourology and Urodynamics, 1993, 12, 23-31.	1.5	2
42	Discriminant analysis using non-metric multidimensional scaling. Pattern Recognition, 1993, 26, 145-153.	8.1	25
43	Clustering Population Means Under Heterogeneity of Variance with an Application to a Rainfall Time Series Problem. Journal of the Royal Statistical Society: Series D (the Statistician), 1992, 41, 113.	0.2	12
44	Clustering Population Means Under Heterogeneity of Variance. Journal of the Royal Statistical Society: Series D (the Statistician), 1992, 41, 591.	0.2	0
45	Robust logistic discrimination. Biometrika, 1991, 78, 841-849.	2.4	14
46	Multidimensional scaling on a sphere. Communications in Statistics - Theory and Methods, 1991, 20, 2943-2953.	1.0	42
47	Multidimensional scaling for n-tuples. British Journal of Mathematical and Statistical Psychology, 1991, 44, 195-206.	1.4	20
48	The generalized likelihood ratio test for the Behrensâ€Fisher problem. Journal of Applied Statistics, 1990, 17, 63-71.	1.3	1
49	Interpreting stress in multidimensional scaling. Journal of Statistical Computation and Simulation, 1990, 37, 211-223.	1.2	8
50	Some Robust Density Estimators for Spatial Point Processes. Biometrics, 1986, 42, 753.	1.4	17
51	Optimising the queuing system for an ear, nose and throat outpatient clinic. Journal of Applied Statistics, 1985, 12, 113-126.	1.3	54
52	The maximum non-unit eigenvalue for the Wright-Fisher model of random genetic drift incorporating selection. Theoretical Population Biology, 1984, 25, 29-40.	1.1	0
53	Nearest neighbours to nearest neighbours. Statistics and Probability Letters, 1983, 1, 161-166.	0.7	1
54	Some Distance-Based Tests of Independence for Sparsely-Sampled Multivariate Spatial Point Patterns. International Statistical Review, 1983, 51, 11.	1.9	35

#	ARTICLE	IF	CITATIONS
55	Reflexive Nearest Neighbours. Biometrics, 1981, 37, 367.	1.4	48
56	A Method for Mapping the Dense and Sparse Regions of a Forest Stand. Journal of the Royal Statistical Society Series C: Applied Statistics, 1979, 28, 14.	1.0	8
57	Probability and Special Relativity. Journal of Applied Statistics, 1979, 6, 57-65.	1.3	1
58	A conditioned distance ratio method for analyzing spatial patterns. Biometrika, 1976, 63, 483-491.	2.4	51
59	The robust estimation of the density of a forest stand using a new conditioned distance method. Biometrika, 1976, 63, 493-499.	2.4	23
60	The Robust Estimation of the Density of a Forest Stand Using a New Conditioned Distance Method. Biometrika, 1976, 63, 493.	2.4	1